Linka Group | Aesthetic Medicine Acquisition Platform

Acquiring cash-generative aesthetic clinics through disciplined underwriting and structured consolidation.

Governance-led. Transaction-focused.
Built for institutional ownership.

European Aesthetic Medicine Platform

About us

Linka Group is a European platform focused on acquiring and consolidating aesthetic medicine clinics.

The market remains highly fragmented, with most clinics operating without institutional-grade financial control, pricing discipline, or succession planning.

We focus exclusively on profitable, well-run clinics and apply structured financial discipline, governance, and reporting from acquisition.

The platform is built to institutional standards from inception, prioritising underwriting quality, capital preservation, and controlled scaling over acquisition volume.

Every transaction is structured with clear downside protection.

Founder & Managing Director

Leads platform strategy, acquisition execution, and capital deployment.

Responsible for deal origination, structuring, and negotiation across all transactions.

Operates with a focus on pricing discipline, downside protection, and disciplined scaling.

Dr. Pierre A. Morgon

Chairman

Karolis Linkevicius

International life sciences executive and board chairman with 35+ years across global pharmaceutical and healthcare organisations.

Former Executive Committee member at Sanofi, Bristol-Myers Squibb, and Aventis Pasteur.

Brings public markets experience, cross-border transaction oversight, and institutional governance at scale.

Provides board-level discipline, capital markets credibility, and strategic oversight.

Karen Sands

CFO with 25+ years operating inside sponsor-led environments, repeatedly selected by tier-one funds including Bain Capital, Montagu, Triton Partners, and Inflexion.

Led 30+ acquisitions, complex refinancings, and multi-site integrations across international businesses.

Owns underwriting discipline, transaction structuring, and capital integrity across the platform.

Leadership

Execution Model

Disciplined and centralised:

Centralised deal screening and underwriting
Standardised acquisition structures
Independent challenge on valuation and risk
Immediate financial control post-acquisition
Phased integration (financial first, operational second)
Disciplined capital allocation across the portfolio

We engage selectively with clinic owners, advisors, and financing partners aligned with long-term value creation.

Acquiring cash-generative aesthetic clinics through disciplined underwriting and structured consolidation.

Governance-led. Transaction-focused.
Built for institutional ownership.

European Aesthetic Medicine Platform